Brain Imaging in Alzheimer Disease

Визуализация головного мозга при болезни Альцгеймера
Keith A. Johnson, Nick C. Fox, Reisa Anne Sperling, William Edward Klunk
2012-01-31

Alzheimer diseaseamyloid imagingbrain imagingmagnetic resonance imagingpositron emission tomography
Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past four decades. Initially, computed tomography (CT) and then magnetic resonance imaging (MRI) were used diagnostically to rule out other causes of dementia. More recently, a variety of imaging modalities including structural and functional MRI and positron emission tomography (PET) studies of cerebral metabolism with fluoro-deoxy-d-glucose (FDG) and amyloid tracers such as Pittsburgh Compound-B (PiB) have shown characteristic changes in the brains of patients with AD, and in prodromal and even presymptomatic states that can help rule-in the AD pathophysiological process. No one imaging modality can serve all purposes as each have unique strengths and weaknesses. These modalities and their particular utilities are discussed in this article. The challenge for the future will be to combine imaging biomarkers to most efficiently facilitate diagnosis, disease staging, and, most importantly, development of effective disease-modifying therapies.
1
CT and MRI initially supported Alzheimer disease evaluation mainly by excluding alternative causes of dementia.
2
Combining imaging biomarkers is identified as the future strategy for efficient diagnosis, disease staging, and development of disease-modifying therapies.
3
Imaging abnormalities can identify the Alzheimer pathophysiological process during prodromal and presymptomatic stages.
4
No single imaging modality serves all clinical purposes because each has distinct strengths and limitations.
5
Structural and functional MRI, FDG-PET, and amyloid-PET reveal characteristic brain changes in Alzheimer disease.

Brain imaging modalities and biomarkers in Alzheimer disease, including structural and functional MRI and PET measures of cerebral metabolism and amyloid deposition

Characteristic imaging changes and the diagnostic, staging, and pathophysiological utility of multimodal imaging across Alzheimer disease, prodromal, and presymptomatic states

Publication Details
Publication Date
2012-01-31
Journal
Cold Spring Harbor Perspectives in Medicine
Publisher
Cold Spring Harbor Laboratory Press
ISSN
2157-1422
Cited by
1028
Access Type
Author Information
Authors
Keith A. Johnson
Nick C. Fox
Reisa Anne Sperling
William Edward Klunk
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%